In a case-control study investigating the thrombotic risk of SLE patients with or without aPL, Tektonidou et al. showed that HCQ treatment duration is associated with protection from thrombosis in both aPL-positive and aPL-negative subjects [70]. Here, FASLG is linked to systemic lupus erythematosus.